MOLN Earnings Date: Mar 11, 2027 (Estimated) — Molecular Partners AG
NASDAQ · Healthcare · Biotechnology
Updated
When is MOLN's next earnings date?
Molecular Partners AG (MOLN) is expected to report Q4 2026 earnings on Thursday, March 11, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.46.
How did MOLN do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Molecular Partners AG posted EPS of -$0.38 versus the -$0.46 estimate, a beat of 17.4%.
How much does MOLN stock move after earnings?
MOLN beat EPS estimates in 1 of its last 6 reported quarters. Over the last 7 reports the stock moved an average of 5.3% (up or down) in the day after earnings.
About Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
🤖 AI Earnings Analysis
Molecular Partners’ Q3 update signals a strategic pivot toward targeted radiotherapy, sharpening focus in a high-risk clinical-stage biotech portfolio. The $0.38 loss beat estimates by $0.08, but absent revenue and clinical catalysts leave execution risk high.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | -0.46 | -0.38 | +17.39% | — | ✅ Beat | — | — | — |
| 2026-08-25 | Q2 2026 | -0.45 | -0.89 | -96.67% | $0 | ❌ Miss | -0.45% | +2.27% | -2.27% |
| 2026-05-12 | Q1 2026 | -0.38 | -0.45 | -17.37% | $0 | ❌ Miss | -0.99% | -7.43% | -8.17% |
| 2026-03-12 | Q4 2025 | -0.38 | -0.41 | -7.89% | $0 | ❌ Miss | -10.40% | -0.43% | -10.62% |
| 2025-10-30 | Q3 2025 | -0.46 | -1.65 | -258.70% | $0 | ❌ Miss | -3.62% | +24.14% | +6.63% |
| 2025-08-25 | Q2 2025 | -0.53 | -0.67 | -26.42% | $0 | ❌ Miss | -7.71% | -9.85% | -12.69% |
| 2025-03-06 | FY 2024 | — | -1.81 | — | $5.6M | — | +2.24% | -10.41% | -27.16% |
| 2024-08-26 | H1 2024 | — | -0.89 | — | $4.8M | — | +11.79% | -8.89% | -25.36% |
Showing last 8 quarters.